The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study
| Autor: | Johanna E. Vriezekolk, E.M. Selten, Lise M Verhoef, Alfons A den Broeder, Marlies E J L Hulscher, Alphons J L de Jong, Frank H J van den Hoogen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty MEDLINE Arthritis Disease Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Pharmacotherapy All institutes and research themes of the Radboud University Medical Center Rheumatology Internal medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Aged 030203 arthritis & rheumatology Biological Products business.industry Perspective (graphical) Patient Preference Middle Aged medicine.disease Discontinuation lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Rheumatoid arthritis Antirheumatic Agents Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] Dose reduction Drug Therapy Combination Female business |
| Zdroj: | Rheumatology, 57, 1947-1955 Rheumatology, 57, 11, pp. 1947-1955 |
| ISSN: | 1462-0324 1947-1955 |
| Popis: | Objectives The aim of this study was to identify the factors that play a role for patients with RA when considering dose reduction (i.e. gradual tapering until discontinuation) of biological DMARDs (bDMARDs), and to determine their relative importance. Methods A mixed methods design was used in which we identified influencing factors by performing semi-structured interviews and ranked these factors using a Maximum Difference Scaling questionnaire. Also, we looked at the influence of several patient characteristics on this ranking. Results For sub study 1 and 2, 22 and 192 patients with RA were included, respectively, in the analyses. Thirty factors were identified from the interviews-characterized into nine themes-and appraised in the questionnaire. Most respondents had a positive attitude towards bDMARD dose reduction. The study showed that patients are concerned that dose reduction will lead to a disease flare that affects their daily life (pain, function). It is important for them to know that it is possible to increase the dose if (further) reduction fails and that the bDMARD will be effective again. Patients value the opinion of their rheumatologist, and being involved in the decision to start tapering is highly ranked as well. The most important factors were consistent between different groups of patients. Conclusion The results from this study facilitate implementation of bDMARD dose reduction; they inform care providers on what is important for patients and provide a basis for shared decision making. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|